

## CURRICULUM VITAE

**INVESTIGATOR NAME** Mariana Hualde  
**INVESTIGATOR NATIONALITY** Argentina  
**LICENSE NUMBER** 93110  
**STUDY LOCATION ADDRESS:** **Centro de Investigaciones Médicas Mar del Plata**  
Av. Colón 3083, 1º, 4º, 5º and 7º floor, B7600FYK Mar del  
Plata. Bs. As. Argentina Tel: 223 491-7628 / 495-6654 – Fax: 223  
4957241

### **EDUCATION: University, date and title obtained**

Facultad de Medicina. Universidad Nacional de Buenos Aires. 1994 **Title:** Physician  
Colegio de Médicos de la Provincia de Buenos Aires – IX Distrito. 2002. **Title:** Infectology Specialist

### **GRADUATE: Specialty, dates, names of institutions**

2017 - Specialist Consultant in Infectious Diseases. Colegio de médicos de la provincia de Buenos Aires.  
2011 - Hierarchical Specialist in Infectious Diseases. Colegio de médicos de la provincia de Buenos Aires.  
1998 a 2001 - Second level Post Basic Residency in Infectious Diseases. HIGA Dr. O. Alende, Mar del Plata.  
1995 a 1998 Medical Clinic Residence. HIGA Dr. O. Alende, Mar del Plata.  
2015 NIDA Clinical Trials Network, course on Good Clinical Practices  
2021 NIDA Clinical Trials Network, course on Good Clinical Practices

### **TEACHING ACTIVITY**

2014- Present. Adjunct Professor of Infectious Diseases, Facultad de Medicina, UFASTA

### **PROFESSIONAL EXPERIENCE**

#### **Current work:**

2018- Present. Member of the Infectious Diseases Society of Mar del Plata. .  
2001- Present. Member of the Argentine Society of Infectious Diseases.-Doctor belonging to the staff of the Centro de Investigaciones Médicas Mar del Plata since 2022.

#### **Previous work:**

- Outpatient Medical Clinic at AMEC (Asociación empleados de Comercio), 1999-2002.
- Outpatient Infectious Disease Service, HIGA Dr. Oscar Alende, since 1999.
- Infection Control, Clínica Colón, since April 2001.
- Infectious disease service, Clínica Colón S.A.A, since 2006.
- Attending Physician AD-Honorem HIGA Infectology Room, Dr. O. Alende, June 1, 2001 – January 31, 2008.
- Professional Assistance Scholarship, Infectious Diseases Room, HIGA Dr. O Alende, February 1, 2008 – September 30, 2008.
- Interim Attending Physician in the Infectious Diseases Room, HIGA Dr. O. Alende, since October 1, 2008.
- Infection Control, EMHSA Sanatorium, October 2011- December 2014.

### **COURSES, CONFERENCES, CONFERENCES AND SYMPOSIUMS**

- III Argentine AIDS Congress (Argentine AIDS Society). Mar del Plata, November 27 to 30, 1997
- II Conference on Infectology FUNCEI. Mar del Plata, November 17, 2000
- III Conference on Infectology FUNCEI. Mar del Plata, October 19, 2001
- 6th International AIDS Symposium. Buenos Aires, 5 to 7 September 2002
- Conference "The new pneumonia (SARS)". Buenos Aires, April 29, 2003
- XI Pan American Congress of Infectology. Cordoba, May 11 to 14, 2003

- VII Argentine AIDS Congress (Argentine AIDS Society). La Plata, November 24 to 26, 2005
- Distance Medical Education in Infectious Diseases of Adults CEDECEN FUNCEI. 2005. 200 hours with Final Evaluation
- VIII Argentine Congress of Infectious Diseases SADI. Mar del Plata, May 22 to 24, 2008. Member of the Local Organizing Committee.
- 9th International AIDS Symposium. Buenos Aires, September 10 to 13, 2008
- IX Argentine Congress of Infectology SADI. Mar del Plata, June 11 and 12, 2009. Member of the Local Organizing Committee
- II National AIDS Congress. Salta, August 26 to 29, 2009.- European Aids Conference Cologne, Germany. November 11 to 14, 2009.
- 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK. November 7 to 11, 2010.
- XIII National Activity Conference on Prevention and Control of Hospital Infections. Mar del Plata, December 15 to 17, 2010.
- IV International Symposium on Virology-Immunology. Panama, November 22 to 24, 2012.
- Conferences on Infectious Diseases in the Interior. Silver Sea. December 7, 2012.
- 7th Conference of the SEIM Soc of Infectious Enf of Mar del Plata. Mar del Plata, August 10 and 11, 2018. Speaker.
- Trend in antiretrovirals use in Latin America & Improving Standards in Latin America. Santiago, Chile, December 13-15, 2018.
- 8th Conference of the SEIM Soc of Infectious Enf of Mar del Plata. Mar del Plata, August 23 and 24, 2019.
- 17th European Aids Conference EACS. Basel, Switzerland, November 6-9, 2019.
- HIV Drug Therapy Glasgow 2020. Virtual. October 05 to 08, 2020.
- XX Argentine Congress of Infectology SADI Virtual, November 26, 27 and 28, 2020.
- XXI Argentine Congress of Infectious Diseases SADI – V Latin American Congress of Traveler Medicine SLAMVI Hybrid, Buenos Aires, October 25, 26 and 27, 2021.
- IX Conference of the SEIM Soc of Infectious Enf of Mar del Plata. Virtual, November 18-20, 2021.
- 32nd ECCMID European Congress of Clinical Microbiology and Infectious Diseases. Virtual, April 23 to 26, 2022.
- XXII Argentine Congress of Infectious Diseases SADI Buenos Aires, September 15, 16 and 17, 2022

### **PAPERS PRESENTED**

- 2000 -Importing Neurocysticercosis. XI SAMIG Congress
- ACV... and its risk factors? XI SAMIG Congress
- 2003 -Comparative Study of Breathalyzer vs. Y 91 Observed –ESCAVYO-. Award for the best work in the area of Epidemiology, from the Argentine Society of Medicine
- 2004 -Functional evaluation of the elderly patient in the office. Published in the Update and Recertification Course in Medical Clinic
- 2011 -Spontaneous pneumomediastinum (Hamman syndrome). I Congress of Internal Medicine of the Atlantic Coast. sea of silver
- Fluctuating focal neurological deficit in HIV patient. I Congress of Internal Medicine of the Atlantic Coast. sea of silver
- 2012 -Atypical presentation of acute abdominal pain in a diabetic patient. XX National Congress of Medicine 2012 of the SAM (Argentine Society of Medicine)

### **PROFESSIONAL EXPERIENCE IN CLINICAL RESEARCH**

- National Syncope Survey. Investigator. Argentine Society of Medicine, Council of Arrhythmias, June 1997. **Sub Investigator**
- International, multicenter, randomized study for the treatment of Community Pneumonia with

Ziracin. Schering-Plough Latin America Research Center, **1997. Sub Investigator**

- Evaluation of the safety and antiviral efficacy of a novel HIV1 protease inhibitor BMS 232632, alone and in combination with D4T and DDI as compared to a reference combination regimen, protocol AI 424-007. Bristol-Myers-Squibb, **1999. Sub Investigator**
- ABT 378 R early access program protocol M 99-046. Abbott, **2000. Sub Investigator**
- Comparison of the Safety and Efficacy of Clarithromycin Immediate Release Tablets (IR) versus Augmentin R for the Treatment of Penicillin-Resistant S. pneumoniae/Macrolide-Resistant S. pneumoniae (PRSP/MRSP) in Community-Acquired Pneumonia, protocol W99-317 . Abbott, **2000. Sub Investigator**
- ESPRIT study with IL2 in HIV+ patients. NIH, **2001. Sub Investigator**
- A randomized, double-blind, multi-center, comparative, phase III study of intravenous BMS-284756 followed by oral BMS-284756 versus intravenous levofloxacin followed by oral levofloxacin in the treatment of community-acquired pneumonia requiring hospitalization. Bristol-Myers-Squibb, **2001. Sub Investigator**
- Randomized, double-blind equivalence study comparing xxxxxxxx and xxxxxxxx within a triple drug combination containing xxxxxxxx and xxxxxxxx in HIV-1 infected patients naïve to antiretroviral treatment. Triangle pharmaceuticals, **2001. Sub Investigator**
- Early Access Program xxxxxxxx. Abbott Laboratories, **2000 Sub Investigator**
- Randomized, double-blind, multicenter, comparative study of xxxxxxxx administered intravenously followed by xxxxxxxx administered orally, versus xxxxxxxx administered intravenously followed by xxxxxxxx administered orally, in the treatment of complicated intra-abdominal infections. Bristol Myers Squibb co., **2002. Sub Investigator**
- Phase III, randomized, double-blind, placebo-loaded, non-inferiority study on the safety and efficacy of xxxxxxx vs. Oral xxxxxxxx in the treatment of patients with esophageal candidiasis-versicor, **2002. Sub Investigator**
- Population pharmacokinetic study conducted with consenting patients who were included in the ver002-4 protocol: Phase III, randomized, double-blind, placebo-loaded, non-inferiority study on the safety and efficacy of intravenous xxxxxxxx ( ver002) vs. Oral Xxxxxxxx in the treatment of patients with esophageal candidiasis- versicor, **2002. Sub Investigator**
- Phase II, double-blind, dose determination study of intravenous xxxxxxxx in complicated lower urinary tract infections or pyelonephritis. Peninsula pharmaceuticals, **2003. Sub Investigator**
- Phase iiib open-label, randomized, multicenter study to evaluate the effect on serum lipids of a switch to protease inhibitor (PI) xxxxxxx, in HIV-1-infected patients who show virologic suppression on their first antiretroviral-containing therapy. ip. Bristol Myers Squibb Co., **2004 Sub Investigator**
- Phase III, randomized, double-blind, multicenter study to compare the safety and efficacy of intravenous xxxxx vs. Xxxxxxx in complicated lower urinary tract infection or pyelonephritis. Peninsula Pharmaceuticals, Inc. **2004. Sub Investigator**
- TFP008 protocol. "Phase III, three-arm, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of tifacogin (recombinant tissue factor pathway inhibitor) administration in subjects with community-acquired pneumonia severe". Chiron, **2004. Sub Investigator**
- "Multicenter, double-blind, randomized, phase III study to evaluate the safety and efficacy of intravenous xxxx vs xxxxxxx in complicated intra-abdominal infections". Peninsula Pharmaceuticals, **2004. Sub Investigator**
- Exploratory study on the effect of the I50I mutation on the response after treatment with xxxx. Bristol Myers Squibb, **2005. Sub Investigator**
- Large and simple study comparing two strategies for the management of antiretroviral therapy (SMART) (cpcra 065) national institute of allergy and infectious diseases. Division of AIDS, **2005 Sub Investigator**
- Multicenter, randomized, open phase III study to compare the safety and efficacy of intravenous xxx vs intravenous xxx in hospital-acquired pneumonia, peninsula pharmaceuticals inc, DORI 09, **2005. Sub Investigator**
- Phase III, randomized, double-blind, multinational study of intravenous telavancin versus vancomycin for the treatment of complicated gram-positive skin and soft tissue infections, targeting

patients with methicillin-resistant staphylococcus aureus infections. Theravance, **2005. Sub Investigator**

- Phase 2, multicenter, randomized, observer-blind study to evaluate the safety and efficacy of xxxxx versus standard treatment in adult subjects with complicated infections of the skin and skin structures. Cerexa, **2005. Sub Investigator**

- Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, tolerability, and safety of xxxx administered as part of antiretroviral (ARV) therapy including xxxx/rtv and an optimized support regimen (OBR). ) selected by the investigator, in HIV-1 infected patients with limited or no therapeutic options. Tibotec, **2006. Sub Investigator**

- 96-week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each combined with fixed doses of tenofovir-emtricitabine, administered in treatment-naïve hiv-1 infected patients. AI424-138. Bristol Myers Squibb, **2006. Sub Investigator**

- Phase III, multicenter, randomized, double-blind, comparative study aimed at evaluating the efficacy and safety of tigecycline, in comparison with the combination Imipenen/Cilastatin in the treatment of patients with hospital-acquired pneumonia. Wyeth 311. **2006. Sub Investigator**

- Open, randomized clinical study to compare the virological efficacy and safety of Atazanavir/Ritonavir with a background regimen of Tenofovir and Emtricitabine vs. Nevirapine with the same background regimen, in patients infected with HIV-1 who have not received prior antiretroviral treatment (ARTEN) BI 1100.1470. **2007 Sub Investigator**

- Phase 3, Multicenter, Randomized, double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftriaxone Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Infections of the Skin and Skin Structures. P903-06, **2007. Sub Investigator**

- Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of xxxxx versus xxxxx in the Treatment of Adult Subjects with Community-Acquired Pneumonia, Protocol P903-09, **2007. Sub Investigator**

- Open-label clinical study with TMC125 as part of antiretroviral therapy (ART) including TMC 114/RTV and an investigator-selected optimized support regimen (OBR) in HIV-1-infected individuals enrolled in a DUET clinical study (TMC125 -C206 or TMC 125-C216), Protocol TMC125C217, **2007. Sub Investigator**

- A randomized, double-blind, double-placebo, parallel-group, active-control study to assess the antiviral efficacy of 400mg once daily xxxxxxxx extended-release formulation compared with 200mg twice daily xxxxxxxx immediate-release in combination with xxxxxxxx in patients infected with HIV-1 without previous antiretroviral treatment. (VERVE) **2008. Sub Investigator** 219700 VOLITION Phase IIIb HIV-1 in antiretroviral therapy-naïve adults Sub Investigator Since 2024

MRXC-302 Phase III Moderate disease or severe diabetic foot infections. Since 2024 Principal Investigator

DATE: 17 Jan 2024

  
SIGNATURE: